{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:53:45Z","timestamp":1775202825727,"version":"3.50.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Low-grade B-cell lymphomas other than follicular and small lymphocytic lymphoma (LGBCL) account for 10% of all B-cell non-Hodgkin lymphomas. Despite improvements in survival outcomes for these patients, little is known about cause of death (COD) in the rituximab era. For a better understanding, we studied 822 newly diagnosed patients with marginal zone, lymphoplasmacytic, and unclassifiable low-grade B-cell lymphoma prospectively enrolled in the University of Iowa\/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2015. COD was assigned based on medical record review using a standard protocol. At a median follow-up of 107 months, 219 (27%) patients had died. The incidence of lymphoma-related deaths when pooling across subtypes was lower than non\u2013lymphoma-related deaths (10-year incidence, 8.0%; 95% confidence interval [CI]: 6.2-10.4 vs 13.6%; 95% CI: 11.2-16.6). The incidence of lymphoma-related deaths varied by subtype, ranging from 3.7% at 10 years in extranodal marginal zone lymphoma to 19.3% in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia. Patients with early progression or retreatment events, defined using event-free survival at 24 months from diagnosis, had significantly higher likelihood of lymphoma-related death compared with patients without early events (10-year estimate: 19.1% vs 5.1%, respectively; P &amp;lt; .001), whereas the rates for non\u2013lymphoma-related death were comparable in patients with or without early events (10-year estimates: 11.0% vs 15.3%, respectively). In conclusion, the most common COD in LGBCLs in the first decade after diagnosis was for causes other than lymphoma. Progression or retreatment within the first 2 years of diagnosis was a strong predictor for risk of lymphoma-related death.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007990","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T18:47:18Z","timestamp":1658170038000},"page":"5210-5221","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study"],"prefix":"10.1182","volume":"6","author":[{"given":"Aung M.","family":"Tun","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"},{"name":"2University of Kansas Cancer Center, University of Kansas, Kansas City, KS;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Mwangi","sequence":"additional","affiliation":[{"name":"3Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7904-1651","authenticated-orcid":false,"given":"Anne J.","family":"Novak","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-0809","authenticated-orcid":false,"given":"Jose C.","family":"Villasboas","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gita","family":"Thanarajasingam","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-9891","authenticated-orcid":false,"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei","family":"Syrbu","sequence":"additional","affiliation":[{"name":"6Department of Pathology, University of Iowa, Iowa City, IA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"7Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"3Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"3Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"6","key":"2022090715234984700_B1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"issue":"9","key":"2022090715234984700_B2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol."},{"issue":"10","key":"2022090715234984700_B3","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","article-title":"Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project","volume":"101","author":"Perry","year":"2016","journal-title":"Haematologica."},{"issue":"6","key":"2022090715234984700_B4","first-page":"1069","article-title":"The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009","volume":"22","author":"Shiels","year":"2013","journal-title":"Am Soc Prev Oncol."},{"issue":"6","key":"2022090715234984700_B5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ajh.25473","article-title":"The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas","volume":"94","author":"Tracy","year":"2019","journal-title":"Am J Hematol."},{"issue":"20","key":"2022090715234984700_B6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"1-2","key":"2022090715234984700_B7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.beha.2016.08.029","article-title":"Transformation of marginal zone lymphoma (and association with other lymphomas)","volume":"30","author":"Casulo","year":"2017","journal-title":"Best Pract Res Clin Haematol."},{"issue":"6","key":"2022090715234984700_B8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.14007","article-title":"Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402","volume":"173","author":"Williams","year":"2016","journal-title":"Br J Haematol."},{"issue":"28","key":"2022090715234984700_B9","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022090715234984700_B10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022090715234984700_B11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol."},{"issue":"8","key":"2022090715234984700_B12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41408-021-00532-1","article-title":"Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J."},{"issue":"8","key":"2022090715234984700_B13","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022090715234984700_B14","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.1999.17.8.2486","article-title":"Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"17","author":"Nathwani","year":"1999","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022090715234984700_B15","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood."},{"issue":"17","key":"2022090715234984700_B16","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2015-12-624296","article-title":"Optimizing therapy for nodal marginal zone lymphoma","volume":"127","author":"Thieblemont","year":"2016","journal-title":"Blood."},{"issue":"6","key":"2022090715234984700_B17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/00000478-200306000-00006","article-title":"Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases","volume":"27","author":"Camacho","year":"2003","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"2022090715234984700_B18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.2006.06437.x","article-title":"Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease","volume":"136","author":"Arcaini","year":"2007","journal-title":"Br J Haematol."},{"issue":"1","key":"2022090715234984700_B19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1349-7006.2006.00345.x","article-title":"Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases","volume":"98","author":"Kojima","year":"2007","journal-title":"Cancer Sci."},{"issue":"2","key":"2022090715234984700_B20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.leukres.2009.04.003","article-title":"2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma","volume":"34","author":"Orciuolo","year":"2010","journal-title":"Leuk Res."},{"issue":"1","key":"2022090715234984700_B21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.27704","article-title":"Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients","volume":"119","author":"Heilgeist","year":"2013","journal-title":"Cancer."},{"issue":"3","key":"2022090715234984700_B22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncr.27773","article-title":"Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Olszewski","year":"2013","journal-title":"Cancer."},{"issue":"7","key":"2022090715234984700_B23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.31821","article-title":"Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes","volume":"125","author":"Hester","year":"2019","journal-title":"Cancer."},{"issue":"6","key":"2022090715234984700_B24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/bjh.16492","article-title":"Cause-specific mortality in individuals with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinaemia, 2000-2016","volume":"189","author":"Dalal","year":"2020","journal-title":"Br J Haematol."},{"issue":"11","key":"2022090715234984700_B25","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.3324\/haematol.2015.124149","article-title":"Competing risk survival analysis in patients with symptomatic Waldenstr\u00f6m macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy","volume":"100","author":"Kastritis","year":"2015","journal-title":"Haematologica."},{"issue":"10","key":"2022090715234984700_B26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.2019001088","article-title":"Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study","volume":"134","author":"Luminari","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2022090715234984700_B27","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","article-title":"Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment","volume":"105","author":"Conconi","year":"2020","journal-title":"Haematologica."},{"issue":"2","key":"2022090715234984700_B28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjh.14228","article-title":"Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era","volume":"175","author":"Starr","year":"2016","journal-title":"Br J Haematol."},{"key":"2022090715234984700_B29","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2019-125008","article-title":"Revised-MALT-IPI: a new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma (EMZL)","volume":"134","author":"Alderuccio","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2022090715234984700_B30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalb\u00e1n","year":"2012","journal-title":"Br J Haematol."},{"issue":"9","key":"2022090715234984700_B31","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br J Cancer."},{"issue":"6","key":"2022090715234984700_B32","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/ije\/dyx119","article-title":"Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) Cohort Study","volume":"46","author":"Cerhan","year":"2017","journal-title":"Int J Epidemiol."},{"issue":"11","key":"2022090715234984700_B33","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood."},{"issue":"5","key":"2022090715234984700_B34","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood."},{"issue":"12","key":"2022090715234984700_B35","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood."},{"key":"2022090715234984700_B36","first-page":"1141"},{"issue":"12","key":"2022090715234984700_B37","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/ajh.25288","article-title":"The association of physical activity before and after lymphoma diagnosis with survival outcomes","volume":"93","author":"Pophali","year":"2018","journal-title":"Am J Hematol."},{"issue":"3","key":"2022090715234984700_B38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hon.2607","article-title":"Cardiovascular mortality among patients with non-Hodgkin lymphoma: differences according to lymphoma subtype","volume":"37","author":"Abuamsha","year":"2019","journal-title":"Hematol Oncol."},{"issue":"23","key":"2022090715234984700_B39","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jnci\/85.23.1932","article-title":"Second cancers among long-term survivors of non-Hodgkin\u2019s lymphoma","volume":"85","author":"Travis","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"2022090715234984700_B40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer."},{"issue":"8","key":"2022090715234984700_B41","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/annonc\/mdq697","article-title":"Risk for second malignancies in non-Hodgkin\u2019s lymphoma survivors: a meta-analysis","volume":"22","author":"Pirani","year":"2011","journal-title":"Ann Oncol."},{"issue":"5","key":"2022090715234984700_B42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.12684","article-title":"Age-time risk patterns of solid cancers in 60\u00a0901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden","volume":"164","author":"Lorenzo Bermejo","year":"2014","journal-title":"Br J Haematol."},{"key":"2022090715234984700_B43","author":"National Comprehensive Cancer Network"},{"issue":"1","key":"2022090715234984700_B44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with\u00a0Waldenstr\u00f6m macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol."},{"issue":"11","key":"2022090715234984700_B45","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/s41375-018-0082-4","article-title":"High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations","volume":"32","author":"Pillonel","year":"2018","journal-title":"Leukemia."},{"issue":"10","key":"2022090715234984700_B46","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood."},{"issue":"11","key":"2022090715234984700_B47","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol."},{"issue":"9","key":"2022090715234984700_B48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/5210\/1918436\/advancesadv2022007990.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/5210\/1918436\/advancesadv2022007990.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T15:25:59Z","timestamp":1662564359000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/17\/5210\/485951\/Causes-of-death-in-low-grade-B-cell-lymphomas-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":48,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,9,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007990","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]}}}